YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Genentech's New and Improved Herceptin

June 4, 2012 | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen. The presented research suggests that the new therapy shrinks tumors in more patients, causes fewer side effects, and keeps patients in remission longer. Xconomy
View Next Related Story
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.